Secondary analysis of two phase 3 trials in adults with severe alopecia areata: of week-52 responders kept on baricitinib, 89.1% (115/129) on 4 mg and 83.6% (56/67) on 2 mg still had SALT ≤20 at week 152, with no new safety signals.
Secondary analysisn = 196
Senna et al. Maintenance of long-term efficacy with continuous baricitinib treatment in patients with severe alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2